[go: up one dir, main page]

UY26648A1 - Inhibidores de vasopeptidasa para tratar hipertensión sistólica aislada - Google Patents

Inhibidores de vasopeptidasa para tratar hipertensión sistólica aislada

Info

Publication number
UY26648A1
UY26648A1 UY26648A UY26648A UY26648A1 UY 26648 A1 UY26648 A1 UY 26648A1 UY 26648 A UY26648 A UY 26648A UY 26648 A UY26648 A UY 26648A UY 26648 A1 UY26648 A1 UY 26648A1
Authority
UY
Uruguay
Prior art keywords
systolic hypertension
isolated systolic
vasopeptidase inhibitors
treat isolated
vasopeptidase
Prior art date
Application number
UY26648A
Other languages
English (en)
Inventor
Richard A Reeves
Robert A Wolf
Paul I Chang
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of UY26648A1 publication Critical patent/UY26648A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se describen los inhibidores de vasopeptidasa especialmente el omapatrilat, que son útiles en el tratamiento de la hipertensión sistólica aislada. El inhibidor de la vasopeptidasa puede ser utilizado en combinación con otros agentes farmacéuticamente activos.
UY26648A 2000-04-03 2001-04-02 Inhibidores de vasopeptidasa para tratar hipertensión sistólica aislada UY26648A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19449900P 2000-04-03 2000-04-03

Publications (1)

Publication Number Publication Date
UY26648A1 true UY26648A1 (es) 2001-11-30

Family

ID=22717832

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26648A UY26648A1 (es) 2000-04-03 2001-04-02 Inhibidores de vasopeptidasa para tratar hipertensión sistólica aislada

Country Status (8)

Country Link
US (1) US20020004500A1 (es)
EP (1) EP1267855A2 (es)
JP (1) JP2003533440A (es)
AU (1) AU2001287289A1 (es)
CA (1) CA2405496A1 (es)
PE (1) PE20011316A1 (es)
UY (1) UY26648A1 (es)
WO (1) WO2001074348A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610716B2 (en) * 2000-07-13 2003-08-26 Alteon Incorporated Cyanomethyl substituted thiazoliums and imidazoliums and treatments of disorders associated with protein aging
US6777443B2 (en) 2001-05-15 2004-08-17 Novartis Ag Dipeptide derivatives
WO2003053353A2 (en) * 2001-12-20 2003-07-03 Bristol-Myers Squibb Company Administration of vasopeptidase inhibitors to reduce pulse pressure
ES2290429T3 (es) * 2002-01-17 2008-02-16 Novartis Ag Composiciones farmaceuticas que comprenden valsartan e inhibidores de nep.
US7468390B2 (en) 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
EP1750862B1 (en) * 2004-06-04 2011-01-05 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
WO2007045663A2 (en) * 2005-10-19 2007-04-26 Novartis Ag Combination of an ati receptor antagonist and a np inhibitor fro treating ia hypertension and heartfailure
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
WO2019108653A1 (en) 2017-11-28 2019-06-06 Anavex Life Sciences Corp. Sigma-1 receptor agonist systolic blood pressure therapy

Also Published As

Publication number Publication date
PE20011316A1 (es) 2002-01-13
WO2001074348A2 (en) 2001-10-11
AU2001287289A1 (en) 2001-10-15
CA2405496A1 (en) 2001-10-11
WO2001074348A8 (en) 2002-05-23
JP2003533440A (ja) 2003-11-11
EP1267855A2 (en) 2003-01-02
US20020004500A1 (en) 2002-01-10

Similar Documents

Publication Publication Date Title
IL158559A0 (en) Acne treatment
EA200101166A1 (ru) Ингибиторы металлопротеаз
PA8468401A1 (es) Compuestos para el tratamiento de la isquemia
ECSP044992A (es) Inhibidores de la alquín-aril fosfodiesterasa-4
EA200800006A1 (ru) Триазолопиридины в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы типа i
ECSP024382A (es) Inhibidores de proteasa de serina
DK1071417T3 (da) Anvendelse af cannabidiol som anti-inflammatorisk middel
ECSP055609A (es) "Uso de inhibidores de la IkB-quinasa para el tratamiento del dolor"
AR109263A2 (es) Composición que comprende moxidectina
UY27203A1 (es) Bencimidazoles útiles en el tratamiento de la disfunción sexual
UY26648A1 (es) Inhibidores de vasopeptidasa para tratar hipertensión sistólica aislada
ATE327973T1 (de) Polyamin-analoge als cytotoxische wirkstoffe
ES2124983T5 (es) Utilizacion de un antagonista de substancia p para el tratamiento de las manchas rojas cutaneas de origen neurogeno.
DE60013486D1 (de) Verbindungen
AR028772A1 (es) 5-aminoalquil-pirazol[4,3-d] pirimidinas
TR200101693T2 (tr) Lemfotoksin (LT) sentezlenme yolunun inhibitörleri kullanılarak foliküler lemfomaların tedavisi.
SE0004101D0 (sv) New use
GT200400241A (es) Prevencion y tratamiento de enfermedades cardiacas hipertensivas mediante el uso de los estrogenos selectivos8b-vinil-estra-1,3,5,(10)-trien-3,17b-diol y 17b-fluor-9a-vinil-estra-1,3,6,(10)-trien-3, 16a-diol
UY27031A1 (es) Uso de agonistas selectivos del receptor de dopamina d4 para tratar disfunción sexual
TR200302134T4 (tr) 2-metil-tiazolidin-2,4-dikarboksilik asit ve/veya bunun fizyolojik olarak uygun tuzlarının anti-kanser ajanları olarak kullanımı.
CY1106289T1 (el) Χρηση αναστολεων υποδοχεος προγεστepονης για τη θepαπευτικη αντιμετωπιση του καρκινου του μαστου που ειναι ανθεκτικος σε στepοειδη
TR200202439T2 (tr) Sodyum hidrojen değiştirici tip 1 önleyici (NHE-1)
BR0009289A (pt) Uso de inibidores da vasopeptidase para tratar angina pectoris
PA8522201A1 (es) Derivados de pirrolidina
AR022620A1 (es) Aroil aminoacil pirroles para ser usados en el tratamiento de dolor neuropatico

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20130218